Narcolepsy Clinical Trials 2024

What are the top hospitals conducting narcolepsy research?

When it comes to advancing our understanding and treatment options for narcolepsy, several hospitals are leading the charge. In Columbia, Bogan Sleep Consultants, LLC is making strides with five active clinical trials focused on narcolepsy. While their overall contribution may seem modest at eight trials since recording their first in 2020, each study brings us closer to unraveling the mysteries of this condition. The Ohio Sleep Medicine Institute in Dublin is also actively involved with five ongoing narcolepsy trials and has an impressive track record of twelve completed studies since their initial trial in 2016.

Meanwhile, in San Antonio's Sleep Therapy and Research Center, researchers are currently engaged in four active narcolepsy trials as part of their commitment to finding innovative solutions for those living with this disorder. Although they have conducted a total of only five trials thus far since beginning their research journey back in 2012, every effort counts towards improving the lives of individuals affected by narcolepsy.

Across the country, Birmingham's Sleep Disorders Center of Alabama stands out with its extensive experience in conducting clinical trials related to this sleep disorder. With four ongoing narcolepsy trials and a remarkable fourteen completed studies dating back to their inaugural trial in 2005, they continue to contribute significantly to advancements within the field.

In Denver's Research Carolina Elite hospital focuses on studying various aspects related to treating Narcolespy; though relatively new compared other institutions presented here but still showcasing dedicated attempts through carrying out four current experiments while already recorded setting-up its very first investigation just two years ago around2019.These efforts collectively demonstrate how these top hospitals are working tirelessly across different locations nationwide towards uncovering groundbreaking insights into narcolepsy while striving toward effective treatments that can significantly improve patients' quality of life.

Which are the best cities for narcolepsy clinical trials?

When it comes to narcolepsy clinical trials, several cities emerge as prominent centers for research and advancement. Cincinnati, Ohio leads the way with 11 active trials exploring treatments like TAK-861 Dose 1, AXS-12 (reboxetine), and SUVN-G3031. Santa Ana, California; Columbia, South carolina; and San Antonio, Texas follow closely behind with eight ongoing studies investigating similar interventions. Additionally, Redwood City, California joins the ranks with seven active trials focused on substances such as TAK-861 Dose 1, JZP258, and AXS-12 (reboxetine). These cities serve as vital hubs for individuals seeking participation in cutting-edge narcolepsy clinical trials that may shape future treatment options for this sleep disorder.

Which are the top treatments for narcolepsy being explored in clinical trials?

Exciting developments are taking place in the field of narcolepsy treatment, with several potential breakthroughs being explored through clinical trials. AXS-12 (reboxetine) is leading the pack, currently undergoing two active trials dedicated to narcolepsy. Its promising debut in 2021 has sparked considerable interest. Also making waves is JZP258, with one ongoing trial focused on narcolepsy and high hopes for its future since its introduction in 2023. Another contender is FT218, which boasts one active trial and two all-time narcolepsy trials following its first listing back in 2016. As researchers delve deeper into these new avenues of treatment, there's renewed optimism for improved management and quality of life for those living with this chronic sleep disorder.

What are the most recent clinical trials for narcolepsy?

Exciting advancements in the field of narcolepsy research have led to recent clinical trials that hold promise for improved treatment options. Among these is JZP258, currently undergoing Phase 4 testing, which aims to address the symptoms associated with narcolepsy. Additionally, TAK-861 Dose 1 has shown potential during its combined Phase 2 and Phase 3 trials for managing this sleep disorder. Another noteworthy trial involves AXS-12 (reboxetine), a medication being evaluated in Phase 3 trials to assess its effectiveness in alleviating symptoms of narcolepsy. These ongoing studies offer hope for individuals living with narcolepsy by presenting new possibilities for better management and increased quality of life moving forward.

What narcolepsy clinical trials were recently completed?

In recent years, several clinical trials have been completed to explore new treatment options for narcolepsy. Notably, NLS Pharmaceutics concluded their investigation into Mazindol in October 2021. Jazz Pharmaceuticals also made significant progress with two separate trials: one involving Solriamfetol 150 mg Oral Tablet (completed in August 2021) and another studying JZP-258 (completed in April 2021). Additionally, Vallon Pharmaceuticals, Inc., successfully wrapped up a trial on ADAIR 10 mg IR tablets in October 2020. While slightly further back in time, Emory University completed a trial evaluating the use of Amphetamine-Dextroamphetamine as a potential treatment for narcolepsy in April 2019. These advancements highlight the ongoing efforts to develop innovative therapies that can improve the lives of those living with this chronic sleep disorder.